Ferric Carboxymaltose – USA

Ferric Carboxymaltose – USA

On Apr. 12, 2018, in one liner decision, Federal Circuit affirmed Patent Trial and Appeal Board’s (PTAB) decision in two IPRs finding certain claims unpatentable.

Previously, PTAB in its decision related to IPR2015-01490 & IPR2015-01493 in Dec 2016 & Jan 2017 found claims of US 7,754,702 and US 8,431,549 unpatentable. These patents are related to administration of stable, high doses of iron. US’702 patent (Exp: 02/13/2027) is listed in Orange Book for INJECTAFER®.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved